This study seeks to assess the associations of Naples Prognostic Score with stroke in adults and all cause mortality among stroke patients. We analyzed data from 44,601 participants in the 2005–2018 National Health and Nutrition Examination Survey (NHANES). The Naples Prognostic Score (NPS) was derived from total cholesterol, serum albumin, neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR). Participants were classified into three groups based on their NPS. Stroke incidence was determined through self-reported questionnaires, and mortality data were diligently tracked using the National Death Index. We investigated the relationship between NPS and stroke prevalence using multiple logistic regression analysis. To explore the association between NPS and all cause mortality in stroke survivors, we applied Kaplan–Meier survival analysis and Cox proportional hazards models. Furthermore, we conducted a detailed subgroup analysis to assess interaction effects on all cause mortality risk within this population. The median age of the participants was 50.00 years [interquartile range: 35.00–64.00], with males comprising 49.36% of the study. The overall stroke prevalence was 3.93%. Participants were categorized into three groups based on their NPS: 6,328 (18.1%) in Group 0 (NPS 0), 24,015 (68.8%) in Group 1 (NPS 1 or 2), and 4,580 (13.1%) in Group 2 (NPS 3 or 4). After adjusting for covariates, individuals in Group 2 exhibited a significantly higher stroke prevalence compared to Group 0, with an odds ratio (OR) of 1.82 [95% confidence interval: 1.48–2.23]. Among the 1372 patients with a history of stroke, with a median follow-up duration of 5.94 years, we utilized Cox proportional hazards models to assess the relationship between NPS and all cause mortality risk. The analysis revealed that, after adjusting for covariates, stroke patients in Group 2 faced a significantly elevated risk of all cause mortality (hazard ratio [HR] = 2.21 [95% confidence interval: 1.44–3.11]) compared to those in Group 0. Subsequent subgroup analyses to explore interaction effects on all cause mortality risk among stroke patients shown no significant interactions (p for interaction > 0.05). This study indicate a positive correlation between NPS and the risk of stroke in adults, as well as all cause mortality in stroke patients.
Background: Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and α -synuclein aggregation. Current treatments do not halt disease progression. Recent research highlights impaired cerebral lymphatic drainage in PD, suggesting a potential therapeutic target. Case presentation: We report a 56-year-old male with advanced PD who underwent deep cervical lymphovenous bypass (DCLB) surgery, a novel intervention designed to enhance lymphatic drainage by anastomosing the deep cervical lymphatic vessel to a vein. The patient had been diagnosed with PD in 2024 after experiencing progressive motor symptoms since 2019, with suboptimal response to conventional pharmacotherapy. Results: At three-month follow-up, significant improvements were observed: Movement Disorder Society–Unified Parkinson’s Disease Rating Scale decreased by 30.4% (from 23 to 16), Non-Motor Symptoms Scale decreased by 71.4% (from 77 to 22), and Parkinson’s Disease Questionnaire-39 decreased by 94.2% (from 52 to 3). Both motor symptoms (rigidity, bradykinesia) and non-motor symptoms (sleep disturbances, orthostatic dizziness) showed improvement. Conclusion: DCLB was technically feasible and was followed by symptomatic improvements in this single patient. The underlying mechanism for this clinical response remains unclear and was not investigated with biomarkers in this report. While these preliminary findings are hypothesis-generating, causality cannot be inferred from an individual case. Further controlled studies incorporating neuroimaging and fluid biomarkers are needed to explore potential mechanisms.
COVID-19-related encephalopathy is a complication of COVID-19 that affects the brain. It can present with symptoms such as altered mental status, ranging from mild confusion to deep coma. It is a major and devastating complication of the SARS-CoV-2 virus. COVID-19-related neurological symptoms may be associated with cytokine release induced by the virus, and tocilizumab targeting IL-6 receptor may provide significant benefits. We report a case of COVID-19-related encephalopathy with cerebrospinal fluid analysis revealing significantly elevated levels of IL-6. Brain magnetic resonance imaging showed a bilateral high signal in the claustrum, and treatment with tocilizumab was effective.
Background: The Naples prognostic score (NPS), derived from routine inflammatory and nutritional biomarkers, reflects systemic immune–metabolic status. Its prospective association with Parkinson disease (PD) risk has not been well established. Methods: We analyzed 317,035 UK Biobank participants recruited in 2006–2010 who were free of PD and malignancy at baseline and had complete NPS component data. NPS was derived from serum albumin, total cholesterol, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. Incident PD through 31 December 2022 was identified using a validated algorithm. Associations were examined using Cox proportional hazards models with multivariable adjustment. Results: Over a median follow-up of 13.94 years, 2,298 participants (0.72%) developed PD. Higher NPS was significantly associated with increased PD risk. After multivariable adjustment, each 1-point increase in NPS corresponded to a 13% higher risk (Model 2 adjusted HR = 1.13, 95% CI: 1.07–1.19, p < 0.001). Compared with participants with NPS = 0, those with moderate to high NPS scores (2–4 points) had progressively elevated risks (NPS = 2: HR = 1.16, 95% CI: 1.03–1.31; NPS = 3: HR = 1.53, 95% CI: 1.29–1.82; NPS = 4: HR = 2.08, 95% CI: 1.21–3.58; all p < 0.05), showing a clear dose–response relationship ( p for trend < 0.001). Conclusion: In this large prospective cohort, higher NPS was independently associated with increased PD risk. These findings support the potential role of integrated inflammatory–nutritional status in PD development and suggest that NPS may serve as a readily available marker for risk stratification.
Background: The association between psychological resilience and Parkinson’s disease (PD) remains unclear at the population level. Methods: We analyzed 147,143 UK Biobank participants with available Brief Resilience Scale (BRS) data and complete covariate information. Parkinson’s disease was ascertained using a previously published UK Biobank algorithm. Multivariable logistic regression was used to examine the association between subsequently assessed BRS scores and prior PD after adjustment for demographic, socioeconomic, lifestyle, clinical, and genetic factors. Restricted cubic splines were used to assess nonlinearity. Results: The mean age was 55.3 years, 56.4% of participants were women, and 346 (0.24%) had Parkinson’s disease. Higher subsequently assessed BRS scores were associated with lower odds of a prior Parkinson’s disease diagnosis. In the fully adjusted model, each 1-point increase in BRS was associated with an OR of 0.63 (95% CI, 0.55–0.73; p < 0.001). Compared with the lowest BRS tertile, the OR was 0.63 (95% CI, 0.50–0.80) for the middle tertile and 0.43 (95% CI, 0.31–0.59) for the highest tertile (P for trend<0.001). Inverse associations were also observed for all six BRS items. The overall association was significant in restricted cubic spline analysis ( p < 0.001), with no evidence of nonlinearity (P for nonlinearity = 0.314). No statistically significant interactions were observed in subgroup analyses. Results were similar in inverse probability-weighted analyses, after additional adjustment for anxiety and depression, and after multiple imputation for missing covariates. Conclusion: Prior Parkinson’s disease diagnosis was associated with lower subsequently assessed self-reported psychological resilience in the UK Biobank. Given the observational design, causality cannot be established.